REAL

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

Thompson, Eric M and Hielscher, Thomas and Bouffet, Eric and Remke, Marc and Luu, Betty and Gururangan, Sridharan and McLendon, Roger E and Bigner, Darell D and Lipp, Eric S and Perreault, Sebastien and Cho, Yoon-Jae and Grant, Gerald and Kim, Seung-Ki and Lee, Ji Yeoun and Rao, Amulya A Nageswara and Giannini, Caterina and Li, Kay Ka Wai and Ng, Ho-Keung and Yao, Yu and Kumabe, Toshihiro and Tominaga, Teiji and Grajkowska, Wieslawa A and Perek-Polnik, Marta and Low, David C Y and Seow, Wan Tew and Chang, Kenneth T E and Mora, Jaume and Pollack, Ian F and Hamilton, Ronald L and Leary, Sarah and Moore, Andrew S and Ingram, Wendy J and Hallahan, Andrew R and Jouvet, Anne and Fèvre-Montange, Michelle and Vasiljevic, Alexandre and Faure-Conter, Cecile and Shofuda, Tomoko and Kagawa, Naoki and Hashimoto, Naoya and Jabado, Nada and Weil, Alexander G and Gayden, Tenzin and Wataya, Takafumi and Shalaby, Tarek and Grotzer, Michael and Zitterbart, Karel and Sterba, Jaroslav and Kren, Leos and Hortobágyi, Tibor and Klekner, Almos and László, Bognár and Pócza, Tímea and Hauser, Peter and Schüller, Ulrich and Jung, Shin and Jang, Woo-Youl and French, Pim J and Kros, Johan M and van Veelen, Marie-Lise C and Massimi, Luca and Leonard, Jeffrey R and Rubin, Joshua B and Vibhakar, Rajeev and Chambless, Lola B and Cooper, Michael K and Thompson, Reid C and Faria, Claudia C and Carvalho, Alice and Nunes, Sofia and Pimentel, José and Fan, Xing and Muraszko, Karin M and López-Aguilar, Enrique and Lyden, David and Garzia, Livia and Shih, David J H and Kijima, Noriyuki and Schneider, Christian and Adamski, Jennifer and Northcott, Paul A and Kool, Marcel and Jones, David T W and Chan, Jennifer A and Nikolic, Ana and Garre, Maria Luisa and Van Meir, Erwin G and Osuka, Satoru and Olson, Jeffrey J and Jahangiri, Arman and Castro, Brandyn A and Gupta, Nalin and Weiss, William A and Moxon-Emre, Iska and Mabbott, Donald J and Lassaletta, Alvaro and Hawkins, Cynthia E and Tabori, Uri and Drake, James and Kulkarni, Abhaya and Dirks, Peter and Rutka, James T and Korshunov, Andrey and Pfister, Stefan M and Packer, Roger J and Ramaswamy, Vijay and Taylor, Michael D (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet. Oncology, 17 (4). pp. 484-95. ISSN 1474-5488

[img] Text
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup.pdf
Restricted to Repository staff only

Download (571kB) | Request a copy

Abstract

BACKGROUND: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and intensified chemoradiotherapy. All previous studies assessing the clinical importance of extent of resection have not accounted for molecular subgroup. We analysed the prognostic value of extent of resection in a subgroup-specific manner. METHODS: We retrospectively identified patients who had a histological diagnosis of medulloblastoma and complete data about extent of resection and survival from centres participating in the Medulloblastoma Advanced Genomics International Consortium. We collected from resections done between April, 1997, and February, 2013, at 35 international institutions. We established medulloblastoma subgroup affiliation by gene expression profiling on frozen or formalin-fixed paraffin-embedded tissues. We classified extent of resection on the basis of postoperative imaging as gross total resection (no residual tumour), near-total resection (<1·5 cm(2) tumour remaining), or sub-total resection (≥1·5 cm(2) tumour remaining). We did multivariable analyses of overall survival and progression-free survival using the variables molecular subgroup (WNT, SHH, group 4, and group 3), age (<3 vs ≥3 years old), metastatic status (metastases vs no metastases), geographical location of therapy (North America/Australia vs rest of the world), receipt of chemotherapy (yes vs no) and receipt of craniospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation). The primary analysis outcome was the effect of extent of resection by molecular subgroup and the effects of other clinical variables on overall and progression-free survival. FINDINGS: We included 787 patients with medulloblastoma (86 with WNT tumours, 242 with SHH tumours, 163 with group 3 tumours, and 296 with group 4 tumours) in our multivariable Cox models of progression-free and overall survival. We found that the prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. We identified a progression-free survival benefit for gross total resection over sub-total resection (hazard ratio [HR] 1·45, 95% CI 1·07-1·96, p=0·16) but no overall survival benefit (HR 1·23, 0·87-1·72, p=0·24). We saw no progression-free survival or overall survival benefit for gross total resection compared with near-total resection (HR 1·05, 0·71-1·53, p=0·8158 for progression-free survival and HR 1·14, 0·75-1·72, p=0·55 for overall survival). No significant survival benefit existed for greater extent of resection for patients with WNT, SHH, or group 3 tumours (HR 1·03, 0·67-1·58, p=0·89 for sub-total resection vs gross total resection). For patients with group 4 tumours, gross total resection conferred a benefit to progression-free survival compared with sub-total resection (HR 1·97, 1·22-3·17, p=0·0056), especially for those with metastatic disease (HR 2·22, 1·00-4·93, p=0·050). However, gross total resection had no effect on overall survival compared with sub-total resection in patients with group 4 tumours (HR 1·67, 0·93-2·99, p=0·084). INTERPRETATION: The prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. Although maximum safe surgical resection should remain the standard of care, surgical removal of small residual portions of medulloblastoma is not recommended when the likelihood of neurological morbidity is high because there is no definitive benefit to gross total resection compared with near-total resection. FUNDING: Canadian Cancer Society Research Institute, Terry Fox Research Institute, Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, and the Garron Family Chair in Childhood Cancer Research.

Item Type: Article
Subjects: R Medicine / orvostudomány > RC Internal medicine / belgyógyászat > RC0254 Neoplasms. Tumors. Oncology (including Cancer) / daganatok, tumorok, onkológia
Depositing User: Dr. Álmos Klekner
Date Deposited: 29 Sep 2016 10:05
Last Modified: 29 Sep 2016 10:05
URI: http://real.mtak.hu/id/eprint/40389

Actions (login required)

Edit Item Edit Item